Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 21346617)

1.

Metabolic effects of olanzapine in patients with newly diagnosed psychosis.

Fernandez-Egea E, Miller B, Garcia-Rizo C, Bernardo M, Kirkpatrick B.

J Clin Psychopharmacol. 2011 Apr;31(2):154-9. doi: 10.1097/JCP.0b013e31820fcea3.

2.

Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study.

Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, Marcy P, Addington J, Estroff SE, Robinson J, Penn DL, Azrin S, Goldstein A, Severe J, Heinssen R, Kane JM.

JAMA Psychiatry. 2014 Dec 1;71(12):1350-63. doi: 10.1001/jamapsychiatry.2014.1314.

PMID:
25321337
3.

Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.

Kemp DE, Zhao J, Cazorla P, Landbloom RP, Mackle M, Snow-Adami L, Szegedi A.

J Clin Psychiatry. 2014 Mar;75(3):238-45. doi: 10.4088/JCP.12m08271.

PMID:
24499969
4.

Atypical antipsychotics for psychosis in adolescents.

Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS.

Cochrane Database Syst Rev. 2013 Oct 15;10:CD009582. doi: 10.1002/14651858.CD009582.pub2. Review.

PMID:
24129841
5.

Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.

Pérez-Iglesias R, Martínez-García O, Pardo-Garcia G, Amado JA, Garcia-Unzueta MT, Tabares-Seisdedos R, Crespo-Facorro B.

Int J Neuropsychopharmacol. 2014 Jan;17(1):41-51. doi: 10.1017/S1461145713001053. Epub 2013 Oct 8.

PMID:
24103107
7.

Metabolic and body mass parameters after treatment with JNJ-37822681, a novel fast-dissociating D2 receptor antagonist, vs olanzapine in patients with schizophrenia.

Daly EJ, Kent JM, Janssens L, Newcomer JW, Hüsken G, De Boer P, Tritsmans L, Schmidt ME.

Ann Clin Psychiatry. 2013 Aug;25(3):173-83.

PMID:
23926573
8.

[Effects of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia].

Shao P, Ou J, Wu R, Fang M, Chen H, Xu Y, Zhao J.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2013 Apr;38(4):365-9. doi: 10.3969/j.issn.1672-7347.2013.04.005. Chinese.

9.

A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients.

Hu S, Yao M, Peterson BS, Xu D, Hu J, Tang J, Fan B, Liao Z, Yuan T, Li Y, Yue W, Wei N, Zhou W, Huang M, Xu Y.

Psychopharmacology (Berl). 2013 Nov;230(1):3-13. doi: 10.1007/s00213-013-3073-1. Epub 2013 Apr 5.

PMID:
23559220
10.

Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.

Jin H, Shih PA, Golshan S, Mudaliar S, Henry R, Glorioso DK, Arndt S, Kraemer HC, Jeste DV.

J Clin Psychiatry. 2013 Jan;74(1):10-8. doi: 10.4088/JCP.12m08001. Epub 2012 Nov 27.

11.
12.

Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.

Wang LJ, Ree SC, Huang YS, Hsiao CC, Chen CK.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:260-6. doi: 10.1016/j.pnpbp.2012.10.010. Epub 2012 Oct 18.

PMID:
23085073
13.

Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia.

Ou JJ, Xu Y, Chen HH, Fan X, Gao K, Wang J, Guo XF, Wu RR, Zhao JP.

Psychopharmacology (Berl). 2013 Feb;225(3):627-35. doi: 10.1007/s00213-012-2850-6. Epub 2012 Aug 28.

PMID:
22926006
14.

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.

De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU.

CNS Drugs. 2012 Sep 1;26(9):733-59. doi: 10.2165/11634500-000000000-00000. Review.

PMID:
22900950
16.

Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.

Schreiner A, Niehaus D, Shuriquie NA, Aadamsoo K, Korcsog P, Salinas R, Theodoropoulou P, Fernández LG, Uçok A, Tessier C, Bergmans P, Hoeben D.

J Clin Psychopharmacol. 2012 Aug;32(4):449-57. doi: 10.1097/JCP.0b013e31825cccad. Erratum in: J Clin Psychopharmacol. 2012 Dec;32(6):803.

PMID:
22722501
17.

Prediabetic increase in hemoglobin A1c compared with impaired fasting glucose in patients receiving antipsychotic drugs.

Manu P, Correll CU, Wampers M, van Winkel R, Yu W, Mitchell AJ, De Hert M.

Eur Neuropsychopharmacol. 2013 Mar;23(3):205-11. doi: 10.1016/j.euroneuro.2012.05.002. Epub 2012 May 29.

PMID:
22652493
18.

Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia.

Sugai T, Suzuki Y, Fukui N, Ono S, Watanabe J, Tsuneyama N, Someya T.

J Clin Psychopharmacol. 2012 Jun;32(3):390-3. doi: 10.1097/JCP.0b013e3182524393.

PMID:
22544005
19.

Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine.

Kryzhanovskaya LA, Xu W, Millen BA, Acharya N, Jen KY, Osuntokun O.

J Child Adolesc Psychopharmacol. 2012 Apr;22(2):157-65. doi: 10.1089/cap.2010.0020. Epub 2012 Feb 28.

PMID:
22372514
20.

Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.

Rosa F, Schreiner A, Thomas P, Sherif T.

Clin Drug Investig. 2012 Apr 1;32(4):267-79. doi: 10.2165/11599080-000000000-00000.

PMID:
22339430
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk